A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction

A Phase 2 Prospective, Randomized, Double-blind, Sham-controlled, Parallel-group, Multi-center Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction

This is a double-blind, sham-controlled clinical study to evaluate the safety and feasibility of AMI MultiStem therapy in subjects who have had a heart attack (Non-ST elevation MI).

Inclusion Criteria:

• Subjects of either gender, 18-85 years of age, inclusive
• Diagnosis of non-ST elevation myocardial infarction (NSTEMI)
• Left Ventricular Ejection Fraction (LVEF) between ≥ 25 and ≤ 45%

Exclusion Criteria:

• Previous Coronary Artery Bypass Graft (CABG)
• Previous autologous, allogeneic bone marrow or peripheral stem cell transplant
• Previous solid organ transplant
• Anticipated need for additional planned coronary revascularization procedure(s)
• Hemodynamic instability
• Mechanical complications of the index acute myocardial infarction